SRN-901, combining urolithin A, quercetin, nicotinamide riboside, alpha-lipoic acid, and proprietary SRN-820, extended median remaining lifespan by 33% in 18-month-old mice while reducing frailty progression by 70%. The combination outperformed individual NAD+ precursors NMN and NR, which showed no lifespan benefits when tested alone, suggesting synergistic effects across multiple aging pathways including inflammation, DNA repair, and glutathione metabolism. This represents a significant advance in translating multi-target aging interventions from theory to practice. The combination approach addresses a fundamental limitation in geroscience—that single compounds targeting isolated pathways have yielded modest results in higher organisms. However, the study's industry sponsorship by Seragon Biosciences raises questions about independent validation, and the proprietary SRN-820 component makes replication impossible. The 33% lifespan extension rivals rapamycin's effects, positioning this as potentially paradigm-shifting if reproduced in independent laboratories. The metabolic profiling showing younger-like blood profiles provides mechanistic credibility, though human translation remains years away given the complexity of scaling multi-compound interventions.